Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675951 | 0.80 | MAOA (0.40) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL26675959 | 0.67 | MAOA (0.45) | NPC1 | |
| SCHEMBL5752697 | 0.64 | NPC1 (0.44) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31662605 | 0.62 | NPC1 (0.47) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL26675896 | 0.62 | HTR2A (0.52) | — | |
| SCHEMBL23538108 | 0.61 | EGFR (0.45) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL16023365 | 0.61 | NPC1 (0.42) | NPC1EGFRIGF1RSRCFLT4 | |
| SCHEMBL29520372 | 0.61 | NPC1 (0.42) | NPC1 | |
| SCHEMBL6259455 | 0.61 | NPC1 (0.42) | NPC1 | |
| SCHEMBL26675974 | 0.61 | NPC1 (0.39) | NPC1EGFRIGF1RSRCFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288048-A1 | OXA-IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | The Trustees Of Columbia University In The City Of New York (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| CN-117120050-A | Oxa-ibogine inspired analogues for the treatment of neurological and psychiatric disorders | 纽约哥伦比亚大学董事会 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022170268-A1 | OXA-IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIA4, GRIA3, GRIN3A | NPC1 1099/4885EGFR 758/4885IGF1R 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.